COVID-19 Vaccination Tracker: Daily Rates, Statistics & Updates
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Covid-19 Vaccination Tracker

Latest news, statistics, daily rates and updates

Last updated 27 September, 2021 10:30 CEST

As the coronavirus vaccine rolls out across the globe, our world Covid-19 vaccine tracker will help you discover the latest Covid-19 updates and live tracking of vaccine development and administration.

You can explore our data and find insights into Covid-19 vaccine clinical trials, country-level vaccination statistics, the impact of vaccination on infection and death rates, and all the latest news and information on the Covid-19 vaccination.

Number of vaccine doses administered globally

6,133,859,009

+16,790,711 reported yesterday

Number of fully vaccinated globally

2,572,860,118

+7,590,323 reported yesterday

Number of countries with a vaccination programme

217

+2 reported yesterday

Fully vaccinated global population

33.9%

+0.3% reported yesterday

Coronavirus vaccine roll out statistics by country

Public health authorities across the globe have been mobilising to deliver the biggest ever vaccination programme to battle Covid-19. How many people have received the Covid-19 vaccine? We bring you the latest Covid-19 vaccine numbers, including daily Covid-19 vaccine rates per country. Track worldwide Covid-19 vaccine rates with Pharmaceutical Technology and GlobalData.

Some countries have made a fast start with their vaccination efforts. By the end of January, Israel had successfully vaccinated 3 million people with the first dose. While the US may have had a slow start, President Biden has put the vaccination programme at the forefront of his first 100 days agenda. View the latest Covid-19 Vaccine Statistics below.

Country Doses Administered Doses per 1000 Fully Vaccinated Population (%) Vaccine being used in a country
World 6,133,859,009 807.7 33.9%
China 2,200,202,000 1,579.8 55.8% CanSino, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, ZF2001
India 855,791,746 632.7 16.6% Covaxin, Oxford/AstraZeneca, Sputnik V
United States 390,114,328 1,192.4 56.1% Johnson&Johnson, Moderna, Pfizer/BioNTech
Brazil 231,844,536 1,106.8 41.6% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Japan 159,494,782 1,260.5 57.3% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Indonesia 134,207,308 501.4 18% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Turkey 107,840,404 1,310.0 52.9% Pfizer/BioNTech, Sinovac
Germany 107,030,469 1,290.6 64.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Mexico 99,186,517 786.0 35.3% CanSino, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
France 93,817,818 1,400.5 65.5% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
United Kingdom 93,461,887 1,405.7 67.3% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Russia 89,301,130 611.9 28.6% EpiVacCorona, Sputnik V
Italy 83,986,620 1,389.8 67.1% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Pakistan 76,141,484 358.8 12% CanSino, Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Spain 69,740,837 1,492.6 77.8% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
South Korea 59,902,869 1,160.1 45% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Canada 55,837,726 1,506.7 72.2% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Argentina 50,755,054 1,140.7 48% CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Thailand 46,023,016 662.9 22.9% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Philippines 43,933,886 411.9 19% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Iran 43,372,270 516.4 16.6% Covaxin, COVIran Barekat, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Malaysia 42,375,862 1,314.9 60.9% CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Saudi Arabia 41,641,404 1,235.7 54.5% Oxford/AstraZeneca, Pfizer/BioNTech
Bangladesh 40,317,634 249.9 10% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Morocco 39,523,919 1,097.0 49.8% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Colombia 39,270,198 791.0 33.1% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Vietnam 38,367,246 401.6 8.3% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Poland 37,147,012 978.1 51% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Chile 31,552,753 1,684.7 75.3% CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Australia 26,660,961 1,066.8 42.6% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Sri Lanka 25,961,797 1,198.1 53.5% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Peru 25,196,478 787.7 31.2% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Cambodia 23,830,570 1,466.5 67% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac
Netherlands 22,272,373 1,292.6 63.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Ecuador 20,571,335 1,204.1 57.6% CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Cuba 19,991,460 1,763.2 43.3% Abdala, Soberana02
United Arab Emirates 19,856,161 2,015.8 82.9% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V
Uzbekistan 18,526,941 562.2 11.2% Oxford/AstraZeneca, Sputnik V, ZF2001
South Africa 16,827,790 291.2 14.5% Johnson&Johnson, Pfizer/BioNTech
Belgium 16,561,256 1,449.9 73.3% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Portugal 15,944,324 1,550.7 83.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Israel 14,932,268 1,680.8 63.2% Moderna, Pfizer/BioNTech
Taiwan 14,430,076 611.2 9.1% Medigen, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Venezuela 14,050,000 486.7 18.2% Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V
Kazakhstan 13,901,899 760.6 35% QazVac, Sinopharm/Beijing, Sputnik V
Egypt 13,808,798 134.9 5% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik V
Sweden 13,607,052 1,336.2 63.7% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Nepal 12,645,634 450.2 21.5% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Ukraine 12,240,363 274.3 12.2% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Greece 12,041,797 1,122.5 56.5% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Hungary 11,826,680 1,210.7 57.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Dominican Republic 11,793,493 1,109.7 45.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Czechia 11,776,675 1,108.3 55.9% Johnson&Johnson, Moderna, Pfizer/BioNTech
Austria 10,792,944 1,220.0 60.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Switzerland 10,330,401 1,213.0 55.5% Moderna, Pfizer/BioNTech
Romania 10,054,036 516.3 27.4% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Algeria 9,989,662 236.6 9.9% Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Singapore 9,286,999 1,647.0 80.1% Moderna, Pfizer/BioNTech, Sinovac
Myanmar 9,001,616 167.6 6.5% Oxford/AstraZeneca, Sinopharm/Beijing
Denmark 8,765,351 1,511.9 75.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Hong Kong 8,574,118 1,134.1 54.5% Pfizer/BioNTech, Sinovac
Azerbaijan 8,349,945 839.8 36.6% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Norway 7,747,721 1,457.9 68% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Finland 7,523,495 1,363.4 61.6% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Iraq 7,448,300 193.8 6.5% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Tunisia 7,425,277 642.0 29.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
El Salvador 7,349,843 1,144.7 51.5% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Ireland 7,195,154 1,482.5 75.5% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Jordan 6,920,178 695.1 32.6% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Guatemala 6,653,056 385.7 13.2% Moderna, Oxford/AstraZeneca
Serbia 6,409,263 918.0 41.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Nigeria 6,255,025 31.9 0.9% Oxford/AstraZeneca
Uruguay 6,162,074 1,786.5 74.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Bolivia 6,124,440 539.4 25.1% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Zimbabwe 5,234,875 362.6 15.2% Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Honduras 5,196,072 542.0 20.7% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Panama 5,127,756 1,227.7 52.9% Oxford/AstraZeneca, Pfizer/BioNTech
New Zealand 5,045,901 1,032.8 37% Pfizer/BioNTech
Qatar 4,696,753 1,688.5 79.8% Moderna, Pfizer/BioNTech
Slovakia 4,685,790 860.2 41.2% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Oman 4,636,486 960.0 37.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Costa Rica 4,580,610 916.2 30.2% Oxford/AstraZeneca, Pfizer/BioNTech
Paraguay 4,488,153 645.2 26.8% Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Laos 4,402,770 605.1 26.2% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Mongolia 4,376,793 1,380.6 67.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Tajikistan 3,872,421 425.5 17.2% Moderna, Oxford/AstraZeneca, Sinovac
Kenya 3,613,357 70.3 1.7% Oxford/AstraZeneca, Sputnik V
Ethiopia 3,535,329 32.4 0.7% Oxford/AstraZeneca
Mozambique 3,427,486 116.2 5.3% Oxford/AstraZeneca, Sinopharm/Beijing
Rwanda 3,409,470 277.1 11.7% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Croatia 3,408,049 833.4 41.4% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Lithuania 3,339,375 1,197.1 58% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Kuwait 3,100,000 749.3 0.9% Pfizer/BioNTech
Lebanon 2,816,322 411.2 18.4% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Bahrain 2,561,756 1,632.3 70.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Belarus 2,541,745 268.0 11.6% Sinopharm/Beijing, Sputnik V
Bulgaria 2,508,560 357.1 18.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Slovenia 2,104,272 1,017.8 47.8% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Angola 2,086,325 67.7 3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Uganda 2,058,553 48.2 1% Oxford/AstraZeneca
Palestine 2,001,407 392.3 12.8% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Afghanistan 1,979,652 53.3 0.5% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Senegal 1,784,832 112.6 3.6% Oxford/AstraZeneca, Sinopharm/Beijing
Georgia 1,749,457 468.9 20.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Guinea 1,699,898 136.9 4.3% Sputnik V
Albania 1,693,555 590.8 26.6% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Mauritius 1,633,952 1,291.4 62.3% Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Ghana 1,623,582 54.5 2.6% Oxford/AstraZeneca, Sputnik V
Latvia 1,616,636 839.1 43.1% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Libya 1,501,622 224.8 2.5% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
North Macedonia 1,495,762 718.1 34.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Kyrgyzstan 1,411,946 223.6 9.5% Sinopharm/Beijing, Sputnik V
Moldova 1,383,749 390.2 21.7% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Estonia 1,359,926 1,029.6 45.8% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Kosovo 1,274,156 690.5 27.3% Oxford/AstraZeneca, Pfizer/BioNTech
Cyprus 1,146,345 905.0 43.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Bosnia and Herzegovina 1,060,145 318.9 12.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Trinidad and Tobago 1,045,498 752.2 34.5% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Malawi 1,030,077 56.8 2.7% Johnson&Johnson, Oxford/AstraZeneca
Bhutan 1,010,129 1,339.0 63.1% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Fiji 975,268 1,103.9 43.8% Oxford/AstraZeneca
Sudan 823,881 19.7 0.3% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Malta 816,767 1,689.2 86.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Nicaragua 788,502 122.0 4.4% Oxford/AstraZeneca, Sputnik V
Luxembourg 771,470 1,269.4 59.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Maldives 727,664 1,411.0 65.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Jamaica 715,860 243.9 7.5% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Zambia 699,210 40.3 2.2% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Togo 651,941 82.6 3% Oxford/AstraZeneca
Macao 649,564 1,028.4 48% Pfizer/BioNTech, Sinopharm/Beijing
Botswana 606,699 269.2 10.1% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Iceland 551,110 1,558.7 77.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Guyana 533,843 685.3 23.4% Oxford/AstraZeneca, Sputnik V
Niger 490,549 21.9 0.4% Oxford/AstraZeneca, Sinopharm/Beijing
Cameroon 459,397 18.2 0.3% Oxford/AstraZeneca, Sinopharm/Beijing
Montenegro 446,806 717.9 33.6% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Brunei 443,676 955.2 37.4% Oxford/AstraZeneca, Sinopharm/Beijing
Somalia 430,762 28.7 1.2% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac
Armenia 408,535 138.4 4.9% Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Namibia 407,502 166.4 6.5% Oxford/AstraZeneca, Sinopharm/Beijing
Cape Verde 402,075 723.2 21.6% Oxford/AstraZeneca, Pfizer/BioNTech
Mali 397,853 20.9 0.5% Oxford/AstraZeneca
Suriname 391,985 680.5 29.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Madagascar 381,633 14.5 0.7% Oxford/AstraZeneca
Equatorial Guinea 360,446 275.4 11.9% Sinopharm/Beijing
Comoros 336,863 404.7 19.5% Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Mauritania 333,089 75.6 0.5% Oxford/AstraZeneca, Sinopharm/Beijing
Lesotho 332,954 157.9 11.3% Oxford/AstraZeneca
Congo 329,905 3.9 0.1% Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Yemen 322,934 11.3 0.1% Johnson&Johnson, Oxford/AstraZeneca
Belize 304,218 794.2 30.1% Oxford/AstraZeneca, Sinopharm/Beijing
Northern Cyprus 302,854 813.1 38.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
French Polynesia 282,180 1,016.2 47.5% Johnson&Johnson, Pfizer/BioNTech
Gambia 277,416 121.7 5.3% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Burkina Faso 254,545 12.2 0.8% Oxford/AstraZeneca
Eswatini 239,551 210.8 17.6% Oxford/AstraZeneca
Barbados 234,124 816.8 35.5% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Sierra Leone 221,110 28.9 0.5% Oxford/AstraZeneca, Sinopharm/Beijing
Tanzania 218,621 3.9 0.4% Johnson&Johnson
New Caledonia 206,784 709.7 27.3% Pfizer/BioNTech
Curacao 186,793 1,168.6 55.7% Moderna, Pfizer/BioNTech
Bahamas 184,461 478.3 18.2% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Gabon 177,392 83.7 3.6% Sinopharm/Beijing, Sputnik V
Benin 174,074 15.2 0.4% Oxford/AstraZeneca, Sinovac
Aruba 155,660 1,470.6 70.4% Pfizer/BioNTech
Central African Republic 150,393 32.2 0.2% Covaxin, Oxford/AstraZeneca
Samoa 149,431 761.9 25.6% Oxford/AstraZeneca
Jersey 144,896 1,344.1 64.9% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Seychelles 141,435 1,461.7 70.9% Oxford/AstraZeneca, Sinopharm/Beijing
Democratic Republic of Congo 134,860 1.6 0% Oxford/AstraZeneca
Isle of Man 129,302 1,537.9 75.9% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Liberia 113,680 23.6 0.6% Oxford/AstraZeneca
Papua New Guinea 113,052 13.1 0.3% Oxford/AstraZeneca
Cayman Islands 109,789 1,710.8 85.5% Oxford/AstraZeneca, Pfizer/BioNTech
Chad 104,707 6.8 0.1% Sinopharm/Beijing
Guernsey 101,759 1,622.8 21.7% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
South Sudan 100,621 9.2 0.3% Oxford/AstraZeneca
Guinea-Bissau 94,715 50.5 0.4% Oxford/AstraZeneca, Sinopharm/Beijing
Bermuda 86,676 1,355.0 66.9% Oxford/AstraZeneca, Pfizer/BioNTech
Gibraltar 79,502 2,357.9 117.4% Pfizer/BioNTech
Greenland 77,822 1,389.1 65.4% Moderna, Pfizer/BioNTech
Saint Lucia 75,827 416.9 17% Oxford/AstraZeneca, Pfizer/BioNTech
Tonga 73,603 696.4 26% Oxford/AstraZeneca
Sao Tome and Principe 73,223 347.0 8.6% Oxford/AstraZeneca
Antigua and Barbuda 71,065 738.1 33.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Djibouti 67,229 70.1 2.7% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Solomon Islands 63,320 97.0 2.2% Oxford/AstraZeneca
Haiti 61,545 5.5 0.2% Johnson&Johnson, Oxford/AstraZeneca
Vanuatu 57,184 195.4 4.9% Oxford/AstraZeneca
Monaco 49,980 1,292.1 60.3% Pfizer/BioNTech
Turks and Caicos Islands 49,107 1,303.8 62.4% Pfizer/BioNTech
Saint Kitts and Nevis 47,098 884.9 41.2% Oxford/AstraZeneca, Pfizer/BioNTech
San Marino 47,084 1,393.6 72.3% Pfizer/BioNTech, Sputnik V
Sint Maarten (Dutch part) 47,084 1,158.2 54.8% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Liechtenstein 46,714 1,232.2 60.3% Moderna, Pfizer/BioNTech
Dominica 44,624 623.0 29.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Turkmenistan 41,993 7.0 0.2% EpiVacCorona, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Grenada 39,121 351.0 15.4% Oxford/AstraZeneca, Pfizer/BioNTech
Saint Vincent and the Grenadines 33,077 300.1 11.9% Oxford/AstraZeneca
Andorra 19,064 247.6 1.6% Oxford/AstraZeneca, Pfizer/BioNTech
Anguilla 18,584 1,028.7 50.3% Oxford/AstraZeneca
Nauru 14,784 1,163.7 57.1% Oxford/AstraZeneca
Wallis and Futuna 10,231 647.2 31.7% Moderna
Bonaire Sint Eustatius and Saba 7,391 275.7 6.2% Moderna, Pfizer/BioNTech
Falkland Islands 4,322 1,070.1 42.5% Oxford/AstraZeneca
Montserrat 1,306 243.7 3.6% Oxford/AstraZeneca

World map of vaccinations – total doses and fully vaccinated

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine numbers as they happen each day.

Total doses tracks the number of vaccine doses applied, whether they be the first or second of the two dose treatments or the one dose vaccine. Fully vaccinated captures the combined number of people to have received either both shots of a two-stage vaccine or the one-shot vaccine. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

The first ever dose of Covid-19 vaccine was administered in the UK in December 2020, and the global vaccination effort has fast expanded with most countries beginning to start their vaccination programmes.

However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out. View the Covid-19 vaccination world map below.

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine first dose and second dose numbers as they happen each day. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

With the worldwide first dose vaccination administered in the UK in December 2020, the global Covid-19 vaccination effort has fast expanded with most countries beginning to start their vaccination programmes. However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

Global Covid-19 vaccinations

This Covid-19 vaccination chart shows a steadily growing Covid-19 vaccination rate globally since January 2021, the first full month of the global Covid-19 vaccination drive. For more details also see GlobalData’s intelligence on Covid-19 vaccinations per country.

Country-level Covid-19 vaccination

With Israel having a head start with Covid-19 vaccine numbers, many countries are stepping up their effort to battle new cases and death rates with fast Covid-19 vaccine roll-outs.

Vaccines administered

Vaccine doses per 1,000 people

Fully vaccinated population

Leading vaccine candidates and current status

At the start of February nine approved Covid-19 vaccines were being used globally to fight the rising global death rate from Covid-19. The Janssen vaccine is likely to achieve imminent approval and there are almost 50 other Covid-19 vaccines still in development. Some might never progress to regulatory approval, but with new variants of Covid-19 spreading fast the race for the most effective and affordable Covid-19 vaccine is still on. Follow GlobalData’s tracker on Covid-19 vaccine initiatives and Covid-19 vaccine trials here:

Progress: Trial Results expected Awaiting approval Available to public
Trial size Doses requierd Storage temperature Efficacy Number of countries approved

Pfizer/BioNTech 46,331 2 8°C to -90°C 95.0% 43

mRNA vaccine, first to demonstrate positive Phase 3 results. Impressive efficacy of 95% in prevention of Covid-19, with a single drawback of requiring unusually cold (-70 degrees F) conditions for storage and transportation.

Trial Start Date - 29 April 2020
Result Publication Date - 18 November 2020
16 Sep, 2021: Complete Approval given by Canada
23 Jun, 2021: Emergency Use Authorization given by Australia
15 Jul, 2021: Emergency Use Authorization given by Indonesia
24 Jun, 2021: Emergency Use Authorization given by Thailand
21 Jun, 2021: Complete Approval given by New-Zealand
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Complete Approval given by US
12 Jun, 2021: Emergency Use Authorization given by Vietnam
11 Jun, 2021: Complete Approval given by Brazil
4 Jun, 2021: Emergency Use Authorization given by UK
2 Jun, 2021: Emergency Use Authorization given by Zambia
31 May, 2021: Emergency Use Authorization given by Pakistan
31 May, 2021: Emergency Use Authorization given by Italy
28 May,2021: Complete Approval given by EU
27 May, 2021: Emergency Use Authorization given by Bangladesh
13 May, 2021: Emergency Use Authorization given by United Arab Emirates
10 May, 2021: Emergency Use Authorization given by US
7 May, 2021: Emergency Use Authorization given by Sri Lanka
6 May, 2021: Emergency Use Authorization given by Canada
16 Mar, 2021: Emergency Use Authorization given by South Africa
15 Mar, 2021: Emergency Use Authorization given by Maldives
5 Mar, 2021: Emergency Use Authorization given by Republic of Korea
1 Mar,2021: Complete Approval given by Denmark
23 Feb,2021: Complete Approval given by Brazil
14 Feb,2021: Complete Approval given by Japan
10 Feb, 2021: Emergency Use Authorization given by New Zealand
2 Feb, 2021: Emergency Use Authorization given by Peru
25 Jan, 2021: Complete Approval given by Australia
25 Jan, 2021: Emergency Use Authorization given by Hong Kong
13 Jan, 2021: Emergency Use Authorization given by Philippines
11 Jan, 2021: Emergency Use Authorization given by Mongolia
6 Jan, 2021: Emergency Use Authorization given by Colombia
27 Dec, 2020: Emergency Use Authorization given by Iraq
25 Dec, 2020: Emergency Use Authorization given by Ireland
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Complete Approval given by EU
21 Dec, 2020: Emergency Use Authorization given by Qatar
19 Dec, 2020: Complete Approval given by Switzerland
17 Dec, 2020: Emergency Use Authorization given by Ecuador
16 Dec, 2020: Emergency Use Authorization given by Panama
16 Dec, 2020: Emergency Use Authorization given by Chile
16 Dec, 2020: Emergency Use Authorization given by Costa Rica
15 Dec, 2020: Emergency Use Authorization given by Oman
15 Dec, 2020: Emergency Use Authorization given by Jordan
14 Dec, 2020: Emergency Use Authorization given by Singapore
13 Dec, 2020: Emergency Use Authorization given by Kuwait
12 Dec, 2020: Emergency Use Authorization given by Mexico
11 Dec, 2020: Emergency Use Authorization given by US
10 Dec, 2020: Emergency Use Authorization given by Saudia Arabia
9 Dec, 2020: Emergency Use Authorization given by Canada
4 Dec, 2020: Emergency Use Authorization given by Bahrain
2 Dec, 2020: Emergency Use Authorization given by UK
Today

Moderna 30,420 2 8°C to -20°C 94.5% 29

Like Pfizer/BioNTech’s offering, is an mRNA vaccine with a nearly identical 95% efficacy for prevention of Covid-19. Also requires freezing temperatures but does not require ultra-low temperatures as Pfizer/BioNTech’s vaccine does.

Trial Start Date - 27 July 2020
Result Publication Date - 16 November 2020
16 Sep, 2021: Complete Approval given by Canada
5 Sep, 2021: Emergency Use Authorization given by Australia
4 Sep, 2021: Emergency Use Authorization given by Philippines
19 Aug, 2021: Emergency Use Authorization given by Mexico
13 Aug, 2021: Emergency Use Authorization given by US
9 Aug, 2021: Emergency Use Authorization given by Australia
5 Aug, 2021: Emergency Use Authorization given by Malaysia
30 Jul, 2021: Emergency Use Authorization given by Lithuania
2 Jul, 2021: Emergency Use Authorization given by Italy
26 Jul, 2021: Emergency Use Authorization given by Bhutan
9 Jul, 2021: Emergency Use Authorization given by Saudia Arabia
4 Jul, 2021: Emergency Use Authorization given by United Arab Emirates
2 Jul, 2021: Emergency Use Authorization given by Indonesia
30 Jun, 2021: Emergency Use Authorization given by India
30 Jun, 2021: Emergency Use Authorization given by Bangladesh
29 Jun, 2021: Emergency Use Authorization given by Vietnam
8 Jun, 2021: Emergency Use Authorization given by Maldives
21 May, 2021: Complete Approval given by South Korea
21 May, 2021: Emergency Use Authorization given by Japan
13 May, 2021: Emergency Use Authorization given by Thailand
6 May, 2021: Emergency Use Authorization given by Taiwan
13 May, 2021: Emergency Use Authorization given by Philippines
30 Apr, 2021: Emergency Use Listing (EUL) given by WHO
9 Feb, 2021: Emergency Use Authorization given by Qatar
3 Feb, 2021: Emergency Use Authorization given by Singapore
12 Jan, 2021: Emergency Use Authorization given by Switzerland
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by UK
8 Jan, 2021: Emergency Use Authorization given by France
6 Jan, 2021: Complete Approval given by EU
4 Jan, 2021: Authorization to import given by Israel
23 Dec, 2020: Emergency Use Authorization given by Canada
18 Dec, 2020: Emergency Use Authorization given by US
Today

AstraZeneca Plc 24,820 2 2 - 8°C 70.4 51

Adenoviral vaccine which has produced mixed results depending on region, vaccine dosing regimen, and schedule. While overall efficacy may be lower than some competitors, protections against hospitalization and death is strong.

Trial Start Date - 28 May 2020
Result Publication Date - 08 December 2020
28 Jul, 2021: Emergency Use Authorization given by New Zealand
2 Jun, 2021: Emergency Use Authorization given by Zambia
21 May, 2021: Emergency Use Authorization given by Japan
25 Mar, 2021: Emergency Use Authorization given by Finland
25 Mar, 2021: Emergency Use Authorization given by Iceland
18 Mar, 2021: Emergency Use Authorization given by Portugal
10 Mar, 2021: Emergency Use Authorization given by Papua New Guinea
10 Mar, 2021: Emergency Use Authorization given by Portugal
8 Mar, 2021: Emergency Use Authorization given by Indonesia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Canada
26 Feb, 2021: Emergency Use Authorization given by Costa Rica
24 Feb, 2021: Emergency Use Authorization given by Colombia
22 Feb, 2021: Emergency Use Authorization given by Ukraine
18 Feb, 2021: Emergency Use Authorization given by Saudi Arabia
18 Feb, 2021: Emergency Use Authorization given by Nigeria
17 Feb, 2021: Emergency Use Authorization given by Iran
16 Feb, 2021: Emergency Use Authorization given by Australia
15 Feb, 2021: Emergency Use Listing (EUL) given by WHO
12 Feb, 2021: Emergency Use Authorization given by Cambodia
10 Feb, 2021: Emergency Use Authorization given by South Korea
6 Feb, 2021: Complete Approval given by Spain
5 Feb, 2021: Emergency Use Authorization given by Greece
2 Feb, 2021: Complete Approval given by France
2 Feb, 2021: Complete Approval given by Sweden
1 Feb, 2021: Emergency Use Authorization given by Vietnam
1 Feb, 2021: Emergency Use Authorization given by Egypt
31 Jan, 2021: Emergency Use Authorization given by Kuwait
30 Jan, 2021: Complete Approval given by Italy
29 Jan, 2021: Complete Approval given by EU
29 Jan, 2021: Emergency Use Authorization given by Philippines
27 Jan, 2021: Emergency Use Authorization given by Chile
24 Jan, 2021: Emergency Use Authorization given by Ecuador
23 Jan, 2021: Emergency Use Authorization given by South Africa
23 Jan, 2021: Emergency Use Authorization given by Bhutan
22 Jan, 2021: Emergency Use Authorization given by Sri Lanka
21 Jan, 2021: Emergency Use Authorization given by Thailand
21 Jan, 2021: Emergency Use Authorization given by Hungary
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Brazil
17 Jan, 2021: Emergency Use Authorization given by Pakistan
15 Jan, 2021: Emergency Use Authorization given by Nepal
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by Bangladesh
6 Jan, 2021: Emergency Use Authorization given by India
6 Jan, 2021: Emergency Use Authorization given by Argentina
6 Jan, 2021: Emergency Use Authorization given by Dominican Republic
6 Jan, 2021: Emergency Use Authorization given by El Salvador
6 Jan, 2021: Emergency Use Authorization given by Mexico
6 Jan, 2021: Emergency Use Authorization given by Morocco
30 Dec, 2020: Emergency Use Authorization given by UK
Today

Novavax Inc 15,203 2 2 - 8°C 90.4% 0

Uses virus-like particles (VLPs) produced in insect cells and demonstrated 100% efficacy against variants "not considered Variants of Concern/Interest" and 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest

Trial Start Date - 28 September 2020
Result Publication Date - 11 March 2021
Today

Johnson & Johnson 44,325 1 2 - 8°C 66.0% 31

Adenoviral vaccine able to confer nearly 70% protection against all Covid-19 with a single dose. Like AstraZeneca’s vaccine, overall protection is not the highest, but offers near-complete protection against hospitalization and death. Also being tested as a two-dose regimen.

Trial Start Date - 07 September 2020
Result Publication Date - 29 January 2021
16 Sep, 2021: Emergency Use Authorization given by Iran
07 Sep, 2021: Emergency Use Authorization given by Indonesia
07 Aug, 2021: Emergency Use Authorization given by India
28 Jul, 2021: Emergency Use Authorization given by Zimbabwe
15 Jul, 2021: Emergency Use Authorization given by Vietnam
7 Jul, 2021: Provisional approval given by New Zealand
5 Jul, 2021: Emergency Use Authorization given by Ukraine
25 Jun, 2021: Provisional approval given by Australia
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Emergency Use Authorization given by Bangladesh
11 Jun, 2021: Emergency Use Authorization given by Chile
8 Jun, 2021: Emergency Use Authorization given by Kuwait
8 Jun, 2021: Emergency Use Authorization given by Maldives
2 Jun, 2021: Emergency Use Authorization given by Zambia
28 May, 2021: Conditional Marketing Authorization given by UK
28 May, 2021: Emergency Use Authorization given by Mexico
20 Apr, 2021: Emergency Use Authorization given by Philippines
8 Apr, 2021: Emergency Use Authorization given by Tunisia
07 Apr, 2021: Conditional Marketing Authorization given by South Korea
1 Apr, 2021: Emergency Use Authorization given by Brazil
26 Mar, 2021: Emergency Use Authorization given by Colombia
25 Mar, 2021: Emergency Use Authorization given by Thiland
26 Mar, 2021: Emergency Use Authorization given by Switzerland
12 Mar, 2021: Conditional Marketing Authorization given by Italy
12 Mar, 2021: Conditional Marketing Authorization given by France
12 Mar, 2021: Emergency Use Listing (EUL) given by WHO
11 Mar, 2021: Conditional Marketing Authorization given by EU
5 Mar, 2021: Emergency Use Authorization given by Canada
27 Feb, 2021: Emergency Use Authorization given by the US
25 Feb, 2021: Emergency Use Authorization given by the US
https://www.aljazeera.com/news/2021/2/17/south-africa-begins-vaccine-rollout-through-observational-study
Today

Gamaleya - Sputnik V 33,758 2 2 - 8°C 91.4% 76

Developed by Russia, uses two different adenoviruses, one for each of two doses, as part of a heterologous vaccination plan. Has shown excellent efficacy of just over 90% in preventing all COVID-19.

Early Approval - 12 August 2020
Trial Start Date - 07 September 2020
Result Publication Date - 14 December 2020
25 Aug, 2021: Emergency Use Authorization given by Indonesia
21 Jul, 2021: Emergency Use Authorization given by Chile
15 Jul, 2021: Emergency Use Authorization given by Nigeria
24 Jun, 2021: Emergency Use Authorization given by Oman
5 Jun, 2020: Conditional Approval given by Brazil
15 May, 2021: Emergency Use Authorization given by Republic of Ecuador
13 May, 2021: Emergency Use Authorization given by Maldives
30 Apr, 2021: Emergency Use Authorization given by Turkey
30 Apr, 2021: Emergency Use Authorization given by Albania
27 Apr, 2021: Emergency Use Authorization given by Bangladesh
20 Apr, 2021: Emergency Use Authorization given by Nepal
12 Apr, 2021: Emergency Use Authorization given by India
1 Apr, 2021: Emergency Use Authorization given by Panama
30 Mar, 2021: Emergency Use Authorization given by Mali
26 Mar, 2021: Emergency Use Authorization given by Antigua
26 Mar, 2021: Emergency Use Authorization given by Barbuda
23 Mar, 2021: Emergency Use Authorization given by Vietnam
22 Mar, 2021: Emergency Use Authorization given by Mauritius
19 Mar, 2021: Emergency Use Authorization given by Cameroon
19 Mar, 2021: Emergency Use Authorization given by Philippines
19 Mar, 2021: Emergency Use Authorization given by Republic of Seychelles
12 Mar, 2021: Emergency Use Authorization given by Azerbaijan
11 Mar, 2021: Emergency Use Authorization given by Namibia
10 Mar, 2021: Emergency Use Authorization given by Jordan
10 Mar, 2021: Emergency Use Authorization given by Kenya
10 Mar, 2021: Emergency Use Authorization given by Morocco
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
7 Mar, 2021: Emergency Use Authorization given by Macedonia
7 Mar, 2021: Emergency Use Authorization given by North Macedonia
4 Mar, 2021: Emergency Use Authorization given by Sri Lanka
4 Mar, 2021: Emergency Use Authorization given by Iraq
4 Mar, 2021: Emergency Use Authorization given by Laos
3 Mar, 2021: Emergency Use Authorization given by Angola
3 Mar, 2021: Emergency Use Authorization given by Djibouti
3 Mar, 2021: Emergency Use Authorization given by Republic of the Congo
1 Mar, 2021: Emergency Use Authorization given by Slovakia
26 Feb, 2021: Emergency Use Authorization given by Republic of Moldova
25 Feb, 2021: Emergency Use Authorization given by Guatemala
24 Feb, 2021: Emergency Use Authorization given by Egypt
24 Feb, 2021: Emergency Use Authorization given by Honduras
23 Feb, 2021: Emergency Use Authorization given by Kyrgyzstan
23 Feb, 2021: Emergency Use Authorization given by Guyana
20 Feb, 2021: Emergency Use Authorization given by Ghana
19 Feb, 2021: Emergency Use Authorization given by San Marino
17 Feb, 2021: Emergency Use Authorization given by Gabon
17 Feb, 2021: Emergency Use Authorization given by Uzbekistan
12 Feb, 2021: Emergency Use Authorization given by Montenegro
12 Feb, 2021: Emergency Use Authorization given by Saint Vincent and the Grenadines
10 Feb, 2021: Emergency Use Authorization given by Bahrain
9 Feb, 2021: Emergency Use Authorization given by Mongolia
9 Feb, 2021: Emergency Use Authorization given by Pakistan
9 Feb, 2021: Emergency Use Authorization given by Mongolia
6 Feb, 2021: Emergency Use Authorization given by Myanmar
6 Feb, 2021: Emergency Use Authorization given by Bosnia and Herzegovina
5 Feb, 2021: Emergency Use Authorization given by Lebanon
3 Feb, 2021: Emergency Use Authorization given by Mexico
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
1 Feb, 2021: Emergency Use Authorization given by Armenia
30 Jan, 2021: Emergency Use Authorization given by Tunisia
29 Jan, 2021: Emergency Use Authorization given by Republic of Guinea
26 Jan, 2021: Emergency Use Authorization given by Iran
21 Jan, 2021: Emergency Use Authorization given by Hungary
21 Jan, 2021: Emergency Use Authorization given by UAE
18 Jan, 2021: Emergency Use Authorization given by Turkmenistan
15 Jan, 2021: Emergency Use Authorization given by Paraguay
14 Jan, 2021: Temporary Registration given by Kazakhstan
13 Jan, 2021: Emergency Use Authorization given by Venezuela
11 Jan, 2021: Emergency Use Authorization given by Palestine
10 Jan, 2021: Emergency Use Authorization given by Algeria
6 Jan, 2021: Emergency Use Authorization given by Bolivia
31 Dec, 2020: Emergency Use Authorization given by Serbia
28 Dec, 2020: Approved by Russia for population aged 60 years and above
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Emergency Use Authorization given by Belarus
12 Aug, 2020: Complete Approval given by Russia
Today

Sinovac Biotech 29,608 2 2 - 8°C 50.7% 28

Vaccine from China, one of few vaccines using inactivated SARS-CoV-2 viruses which is a much more conventional vaccine technology than others which have demonstrated positive Phase III data.

Early Approval - 11 January 2021
Trial Start Date - 21 July 2020
Result Publication Date - 05 February 2021
25 Aug, 2021: Emergency Use Authorization given by Saudi Arabia
17 Jul, 2021: Emergency Use Authorization given by Sri Lanka
3 Jul, 2021: Emergency Use Authorization given by South Africa
24 Jun, 2021: Emergency Use Authorization given by Oman
11 Jun, 2021: Emergency Use Authorization given by China
6 Jun, 2021: Emergency Use Authorization given by Bangladesh
4 Jun, 2021: Emergency Use Authorization given by Nepal
2 Jun, 2021: Emergency use listing (EUL) given by WHO
27 Apr, 2021: Emergency Use Authorization given by Egypt
10 Apr, 2021: Emergency Use Authorization given by Pakistan
9 Apr, 2021: Emergency Use Authorization given by Panama
10 Mar, 2021: Complete Approval given by Ukraine
10 Mar, 2021: Emergency Use Authorization given by Zimbabwe
05 Mar, 2021: Complete Approval given by Tunisia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Hong Kong
26 Feb, 2021: Emergency Use Authorization given by Ecuador
22 Feb, 2021: Emergency Use Authorization given by Philippines
22 Feb, 2021: Emergency Use Authorization given by Thailand
13 Feb, 2021: Emergency Use Authorization given by Cambodia
11 Feb, 2021: Emergency Use Authorization given by Mexico
8 Feb, 2021: Emergency Use Authorization given by China
6 Feb, 2021: Emergency Use Authorization given by Lao People's Democratic Republic
6 Feb, 2021: Emergency Use Authorization given by Uruguay
5 Feb, 2021: Emergency Use Authorization given by Colombia
21 Jan, 2021: Emergency Use Authorization given by Chile
18 Jan, 2021: Emergency Use Authorization given by Brazil
13 Jan, 2021: Emergency Use Authorization given by Turkey
11 Jan, 2021: Emergency Use Authorization given by Indonesia
Today

Sinopharm 60,000+ 2 2 - 8°C 86.0% 35

The second inactivated vaccine, also being developed by China, has shown mixed results in Brazil, where initial efficacy was 86% based on data from the UAE, but efficacy data from Brazil were significantly lower at only 50%.

Early Approval - 10 December 2020
Trial Start Date - 16 July 2020
Result Publication Date - 31 December 2020
21 Aug, 2021: Emergency Use Authorization given by Mexico
25 Aug, 2021: Emergency Use Authorization given by Saudi Arabia
24 Aug, 2021: Emergency Use Authorization given by Nigeria
19 Aug, 2021: Emergency Use Authorization given by Kenya
16 Jul, 2021: Emergency Use Authorization given by Malaysia
12 Jul, 2021: Emergency Use Authorization given by Tunisia
9 Jul, 2021: Emergency Use Authorization given by Trinidad and Tobago
18 Jun, 2021: Emergency Use Authorization given by Gambia
11 Jun, 2021: Emergency Use Authorization given by China
7 Jun, 2021: Emergency Use Authorization given by Philippines
4 June, 2021: Emergency Use Authorization given by Vietnam
2 Jun, 2021: Emergency Use Authorization given by Zambia
29 May, 2021: Emergency Use Authorization given by Bangladesh
28 May, 2021: Emergency Use Authorization given by Thailand
07 May, 2021: Emergency Use Authorization given by WHO
29 Apr, 2021: Emergency Use Authorization given by Indonesia
20 Mar, 2021: Emergency Use Authorization given by Sri Lanka
16 Mar, 2021: Emergency Use Authorization given by Maldives
11 Mar, 2021: Emergency Use Authorization given by Iran
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
1 Mar, 2021: Emergency Use Authorization given by Venezuela
26 Feb, 2021: Emergency Use Authorization given by Guyana
22 Feb, 2021: Emergency Use Authorization given by Argentina
18-Feb, 2021: Emergency Use Authorization given by Nepal
4 Feb, 2021: Emergency Use Authorization given by Cambodia
29 Jan, 2021: Emergency Use Authorization given by Hungary
27 Jan, 2021: Emergency Use Authorization given by Peru
24 Jan, 2021: Emergency Use Authorization given by Morocco
19 Jan, 2021: Emergency Use Authorization given by Pakistan
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Republic of Serbia
9 Jan, 2021: Emergency Use Authorization given by Jordan
4 Jan, 2021: Emergency Use Authorization given by Egypt
2 Jan, 2021: Emergency Use Authorization given by China
14 Dec, 2020: Emergency Use Authorization given by Bahrain
10 Dec, 2020: Complete Approval given by UAE
Today

CanSino Biologics 40,000 1 2 - 8°C 65.7% 9

Like Johnson & Johnson’s vaccine, this vaccine from China showed just under 70% efficacy in preventing all COVID-19 and 90% efficacy in preventing severe COVID-19 with just a single dose.

07 Sep, 2021: Emergency Use Authorization given by Indonesia
16 Jun, 2021: Complete approval given by Ecuador
15 Jun, 2021: Emergency Use Authorization given by Malaysia
12 Jun, 2021: Emergency Use Authorization given by Argentina
8 Apr, 2021: Emergency Use Authorization given by Chile
22 Mar, 2021: Emergency Use Authorization given by Hungary
12 Feb, 2021: Emergency Use Authorization given by Pakistan
11 Feb, 2021: Emergency Use Authorization given by Mexico
25 Jun, 2020: Military Use Authorization given by China
Trial Start Date - 15 September 2020
Today

Bharat Biotech 25,800 2 2 - 8°C 81.0% 7

Adjuvanted inactivated vaccine produced in Vero cells and developed by India, showed 81% efficacy in preventing COVID-19 after two doses.

20 Apr, 2021: Emergency Use Authorization given by Philippines
6 Apr, 2021: Emergency Use Authorization given by Mexico
26 Mar, 2021: Complete Approval given by Mauritius
21 Mar, 2021: Emergency Use Authorization given by Nepal
04 Mar, 2021: Emergency Use Authorization given by Zimbabwe
19 Feb, 2021: Emergency Use Authorization given by Iran
3 Jan, 2021: Restricted Emergency Use Authorization given by India
Trial Start Date - 16 November 2020
Today

Gamaleya - Sputnik Light 110 1 2 - 8°C 79.4% 15

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V, showed 79.4% efficacy from 28 days after the injection was administered as part of Russia’s mass vaccination program.

16 Sep, 2021: Emergency Use Authorization given by Iran
06 Sep, 2021: Complete Approval given by Armenia
23 Aug, 2021: Emergency Use Authorization given by Philippines
15 Jul, 2021: Complete Approval given by Kazakhstan
25 Jun, 2021: Emergency Use Authorization given by Kyrgyzstan
11 Jun, 2021: Emergency Use Authorization given by Mongolia
7 Jun, 2021: Emergency Use Authorization given by Republic of the Congo
3 Jun, 2021: Emergency Use Authorization given by Belarus
2 Jun, 2021: Emergency Use Authorization given by Mauritius
31 May, 2021: Emergency Use Authorization given by Palestine
21 May, 2021: Emergency Use Authorization given by Nicaragua
15 May, 2021: Emergency Use Authorization given by Venezuela
12 May, 2021: Emergency Use Authorization given by Angola
11 May, 2021: Emergency Use Authorization given by Bahrain
6 May, 2021: Complete Approval given by Russia
Trial Start Date - 15 January 2021
Today

Cadila Healthcare Ltd - ZyCoV-D 28,000+ 3 2 - 8°C 66.6% 1

ZyCoV-D is the first plasmid DNA, needle-free vaccine against COVID-19, showing 66.6% efficacy after the third injection was administered in over 28,000 volunteers at more than 50 clinical sites spread across India.

20 Aug, 2021: Emergency Use Authorization given by India
Trial Start Date - 20 January 2021
Today

Covid-19 vaccine clinical trials by region

Covid-19 vaccine clinical trials by trial phase

Covid-19 vaccine clinical trials by trial status

Covid-19 - The race to herd immunity

According to the World Health Organization (WHO), "Herd Immunity, also known as population immunity, is the indirect protection from an infectious disease that happens when a population is immune either through vaccination or immunity developed through previous infection."

Herd immunity against Covid-19 has been widely debated over the past months, however WHO has admitted, "we do not have a clear understanding of the herd immunity level for Covid-19."

So, what is the herd immunity percentage for Covid-19?

In the context of Covid-19, herd immunity level is 60-70%,but could be higher if the new variants of the virus are more contagious.

The assumption should always be higher rather than lower with some recent research suggesting the number of the population that needed to be vaccinated ranged from 69-93%.

Race to herd immunity (Top 20 countries by vaccination rate)

Race to herd immunity (Leading economies)

GlobalData Reports

View More

Up Next

Receive our newsletter Sign up to our e-Newsletter here

Close